GT Biopharma (NASDAQ:GTBP – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($1.98) earnings per share for the quarter, topping the consensus estimate of ($2.50) by $0.52, reports.
GT Biopharma Stock Performance
GT Biopharma stock traded up $0.18 during mid-day trading on Wednesday, hitting $3.36. The company’s stock had a trading volume of 26,367 shares, compared to its average volume of 55,267. The company has a 50 day moving average of $6.10 and a 200-day moving average of $9.01. The stock has a market cap of $6.93 million, a PE ratio of -0.02 and a beta of 0.88. GT Biopharma has a one year low of $3.10 and a one year high of $23.60.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on GTBP. Weiss Ratings reiterated a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, October 2nd. Wall Street Zen lowered GT Biopharma to a “strong sell” rating in a report on Saturday, September 12th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, GT Biopharma has an average rating of “Sell”.
View Our Latest Report on GTBP
About GT Biopharma
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research centers on its TriKE platform, which is designed to direct natural killer (NK) cells toward cancer cells and support their activity using an immune-stimulating signal. The company’s pipeline includes GTB-3650, a candidate designed to target CD33-expressing blood cancers such as acute myeloid leukemia, and GTB-5550, a candidate targeting B7-H3, a protein found on various solid tumors.
See Also
- Five stocks we like better than GT Biopharma
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
